Body Weight and BMI Impact

Added August 18, 2026 — the GLP-1 drugs reach the ankle literature, and the signal points both ways

→ Ozempic-class weight-loss drugs finally got studied for ankle arthritis specifically. In people with obesity, those taking the drugs were half as likely to end up with an ankle replacement over the study window. In diabetics, they were nearly twice as likely to get ankle arthroscopy. Weight loss helps the joint; the full story is messier.

This page has argued since 2025 that body weight is the most modifiable variable in any ankle-surgery outcome. What it has never had is ankle-specific evidence about the drug class currently transforming obesity medicine. That arrived August 17: a TriNetX national-claims cohort study of GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide) in patients with ankle osteoarthritis, from Amiethab Aiyer’s group [425].

• Obese cohort (3,089 matched per arm): GLP-1 users had a lower risk of ankle joint injection (HR 0.8) and half the risk of proceeding to total ankle replacement (HR 0.5, CI 0.3–0.9); arthroscopy no different.
• Diabetic cohort (8,117 matched per arm): arthroscopy risk nearly doubled (HR 1.9, CI 1.2–3.2); injections and replacement unchanged.
• GLP-1 users lost more weight over five years in both cohorts (−2.7 vs −1.6 kg/m² in the obese arm).

Honest limits: Level III retrospective claims data — who gets a procedure is not the same as how a joint feels or looks, and healthier-user bias cannot be excluded from this design. The cohorts are obese or diabetic patients with ankle OA — not a normal-BMI patient with a focal osteochondral lesion, which is this case. Nothing here is a reason to take or avoid these drugs. What it is: the first ankle-specific entry in what will clearly become a literature, and one more datapoint for this page’s standing claim — in the cohort where the drugs primarily drive weight loss, the joint’s surgical trajectory bent measurably away from the operating room.

2025 German Cartilage Registry Data

→ Extra weight = more stress on ankle cartilage with every step. Obesity linked to worse surgical outcomes. Like driving on a weak tire - heavier load = faster wear. Weight management can significantly affect how well treatments work.

A 2025 study from the German Cartilage Registry (303 patients) examined BMI impact on OLT surgical outcomes [107]:

• Both normal weight (BMI <30) and obese (BMI ≥30) groups showed significant improvement
• Higher BMI associated with higher prevalence of ankle sprains and OCTs
• Obesity incidence is rapidly increasing, making this clinically important

2024 JBJS Long-Term Survival

The 10-year survival study analyzed BMI as a risk factor for treatment failure [22]:

• BMI ≥30 kg/m² was included as a prognostic factor
• 82% 10-year survival overall, with obesity as potential modifier

Takeaway: While not a contraindication to surgery, maintaining healthy weight optimizes outcomes.